Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

Abstract

Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.

Activated mouse eosinophils protect against lethal respiratory virus infection

“…Although the disease is heterogeneous in nature, 1,2 eosinophilic leukocytes are typically identified as components of airway infiltrates in childhood asthma 3 and are particularly numerous in the recently defined eosinophilic asthma phenotype. 4,5 Mouse models of allergic airways inflammation suggest that eosinophils promote pathology, including mucus accumulation, airway hyper-responsiveness, and tissue remodeling. 6,7 Respiratory viruses play a major part in promoting asthma exacerbations; meanwhile, several studies have documented a role for eosinophils in limiting virus infectivity and promoting virion clearance.…”

Severe eosinophilic asthma: therapeutic potential of Reslizumab

“…Реслизумаб -это гуманизированное моноклональное антитело против IL-5, разработанное для лечения пациентов с неконтролируемой БА эозинофильного фенотипа [26].…”

Pharmacological Therapy of Bronchial Asthma: The Role of Biologicals

“…Animal studies revealed a 75% decrease in eosinophil accumulation, and current clinical trials have shown a nonsignificant decrease in the asthma exacerbation rate [52]. …”